MONTE ROSA THERAPEUTICS INC (GLUE) Stock Fundamental Analysis

NASDAQ:GLUE • US61225M1027

18.06 USD
-0.03 (-0.17%)
Last: Feb 26, 2026, 11:41 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

Taking everything into account, GLUE scores 5 out of 10 in our fundamental rating. GLUE was compared to 521 industry peers in the Biotechnology industry. GLUE has an excellent financial health rating, but there are some minor concerns on its profitability. GLUE is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year GLUE was profitable.
  • In the past year GLUE had a positive cash flow from operations.
  • GLUE had negative earnings in each of the past 5 years.
  • GLUE had negative operating cash flow in 4 of the past 5 years.
GLUE Yearly Net Income VS EBIT VS OCF VS FCFGLUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

  • With an excellent Return On Assets value of 4.56%, GLUE belongs to the best of the industry, outperforming 90.59% of the companies in the same industry.
  • GLUE has a Return On Equity of 8.52%. This is amongst the best in the industry. GLUE outperforms 91.75% of its industry peers.
  • With an excellent Return On Invested Capital value of 1.69%, GLUE belongs to the best of the industry, outperforming 89.25% of the companies in the same industry.
Industry RankSector Rank
ROA 4.56%
ROE 8.52%
ROIC 1.69%
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
GLUE Yearly ROA, ROE, ROICGLUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • Looking at the Profit Margin, with a value of 11.54%, GLUE belongs to the top of the industry, outperforming 91.17% of the companies in the same industry.
  • With an excellent Operating Margin value of 4.69%, GLUE belongs to the best of the industry, outperforming 89.44% of the companies in the same industry.
Industry RankSector Rank
OM 4.69%
PM (TTM) 11.54%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLUE Yearly Profit, Operating, Gross MarginsGLUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • GLUE has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, GLUE has more shares outstanding
  • Compared to 5 years ago, GLUE has more shares outstanding
  • GLUE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GLUE Yearly Shares OutstandingGLUE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
GLUE Yearly Total Debt VS Total AssetsGLUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • GLUE has an Altman-Z score of 3.73. This indicates that GLUE is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 3.73, GLUE is doing good in the industry, outperforming 68.91% of the companies in the same industry.
  • GLUE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 3.73
ROIC/WACC0.19
WACC8.68%
GLUE Yearly LT Debt VS Equity VS FCFGLUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 6.54 indicates that GLUE has no problem at all paying its short term obligations.
  • The Current ratio of GLUE (6.54) is better than 66.60% of its industry peers.
  • A Quick Ratio of 6.54 indicates that GLUE has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 6.54, GLUE is doing good in the industry, outperforming 67.37% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.54
Quick Ratio 6.54
GLUE Yearly Current Assets VS Current LiabilitesGLUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 116.94% over the past year.
  • The Revenue has grown by 1112.27% in the past year. This is a very strong growth!
EPS 1Y (TTM)116.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.79%
Revenue 1Y (TTM)1112.27%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%38.54%

3.2 Future

  • The Earnings Per Share is expected to decrease by -14.73% on average over the next years. This is quite bad
  • The Revenue is expected to grow by 22.59% on average over the next years. This is a very strong growth
EPS Next Y72.12%
EPS Next 2Y-12.89%
EPS Next 3Y-16.45%
EPS Next 5Y-14.73%
Revenue Next Year431.8%
Revenue Next 2Y47.38%
Revenue Next 3Y36.35%
Revenue Next 5Y22.59%

3.3 Evolution

GLUE Yearly Revenue VS EstimatesGLUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
GLUE Yearly EPS VS EstimatesGLUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • GLUE is valuated quite expensively with a Price/Earnings ratio of 58.26.
  • Based on the Price/Earnings ratio, GLUE is valued cheaply inside the industry as 90.02% of the companies are valued more expensively.
  • GLUE's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.05.
  • The Forward Price/Earnings Ratio is negative for GLUE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 58.26
Fwd PE N/A
GLUE Price Earnings VS Forward Price EarningsGLUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, GLUE is valued cheaper than 91.55% of the companies in the same industry.
  • 98.66% of the companies in the same industry are more expensive than GLUE, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 9.08
EV/EBITDA 44.24
GLUE Per share dataGLUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • GLUE's earnings are expected to decrease with -16.45% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.81
PEG (5Y)N/A
EPS Next 2Y-12.89%
EPS Next 3Y-16.45%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for GLUE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MONTE ROSA THERAPEUTICS INC

NASDAQ:GLUE (2/26/2026, 11:41:02 AM)

18.06

-0.03 (-0.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-12
Inst Owners105.54%
Inst Owner Change6.6%
Ins Owners0.81%
Ins Owner Change1.5%
Market Cap1.32B
Revenue(TTM)181.54M
Net Income(TTM)20.95M
Analysts85.33
Price Target29.87 (65.39%)
Short Float %10.62%
Short Ratio4.38
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.53%
Min EPS beat(2)13.2%
Max EPS beat(2)61.87%
EPS beat(4)4
Avg EPS beat(4)354.59%
Min EPS beat(4)13.2%
Max EPS beat(4)1080.39%
EPS beat(8)7
Avg EPS beat(8)177.66%
EPS beat(12)11
Avg EPS beat(12)119.51%
EPS beat(16)13
Avg EPS beat(16)84.82%
Revenue beat(2)2
Avg Revenue beat(2)120.76%
Min Revenue beat(2)110.55%
Max Revenue beat(2)130.97%
Revenue beat(4)4
Avg Revenue beat(4)277.19%
Min Revenue beat(4)110.55%
Max Revenue beat(4)444.91%
Revenue beat(8)6
Avg Revenue beat(8)183.66%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.86%
PT rev (3m)75.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.63%
EPS NY rev (1m)0%
EPS NY rev (3m)12.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.93%
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.23%
Valuation
Industry RankSector Rank
PE 58.26
Fwd PE N/A
P/S 7.25
P/FCF 9.08
P/OCF 8.83
P/B 5.36
P/tB 5.36
EV/EBITDA 44.24
EPS(TTM)0.31
EY1.72%
EPS(NY)-1.3
Fwd EYN/A
FCF(TTM)1.99
FCFY11.01%
OCF(TTM)2.05
OCFY11.32%
SpS2.49
BVpS3.37
TBVpS3.37
PEG (NY)0.81
PEG (5Y)N/A
Graham Number4.85
Profitability
Industry RankSector Rank
ROA 4.56%
ROE 8.52%
ROCE 2.14%
ROIC 1.69%
ROICexc 94.17%
ROICexgc 94.17%
OM 4.69%
PM (TTM) 11.54%
GM N/A
FCFM 79.89%
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 49.42%
Cap/Sales 2.27%
Interest Coverage 250
Cash Conversion 885.62%
Profit Quality 692.36%
Current Ratio 6.54
Quick Ratio 6.54
Altman-Z 3.73
F-Score8
WACC8.68%
ROIC/WACC0.19
Cap/Depr(3y)233.13%
Cap/Depr(5y)356.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)116.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.79%
EPS Next Y72.12%
EPS Next 2Y-12.89%
EPS Next 3Y-16.45%
EPS Next 5Y-14.73%
Revenue 1Y (TTM)1112.27%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%38.54%
Revenue Next Year431.8%
Revenue Next 2Y47.38%
Revenue Next 3Y36.35%
Revenue Next 5Y22.59%
EBIT growth 1Y106.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.16%
EBIT Next 3Y42.19%
EBIT Next 5YN/A
FCF growth 1Y218.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y253.12%
OCF growth 3YN/A
OCF growth 5YN/A

MONTE ROSA THERAPEUTICS INC / GLUE FAQ

Can you provide the ChartMill fundamental rating for MONTE ROSA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 5 / 10 to GLUE.


What is the valuation status of MONTE ROSA THERAPEUTICS INC (GLUE) stock?

ChartMill assigns a valuation rating of 4 / 10 to MONTE ROSA THERAPEUTICS INC (GLUE). This can be considered as Fairly Valued.


What is the profitability of GLUE stock?

MONTE ROSA THERAPEUTICS INC (GLUE) has a profitability rating of 4 / 10.


Can you provide the PE and PB ratios for GLUE stock?

The Price/Earnings (PE) ratio for MONTE ROSA THERAPEUTICS INC (GLUE) is 58.26 and the Price/Book (PB) ratio is 5.36.


Can you provide the financial health for GLUE stock?

The financial health rating of MONTE ROSA THERAPEUTICS INC (GLUE) is 8 / 10.